Details

Autor(en) / Beteiligte

• FUJIWARA, Keiichi
• UEOKA, Hiroshi
• HARITA, Shingo
• OKIMOTO, Niro
• TANIMOTO, Mitsune
• KIURA, Katsuyuki
• TABATA, Masahiro
• TAKIGAWA, Nagio
• HOTTA, Katsuyuki
• UMEMURA, Shigeki
• SUGIMOTO, Keisuke
• SHIBAYAMA, Takuo
• KAMEI, Haruhito

Titel

A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer

Ist Teil von

• Cancer chemotherapy and pharmacology, 2006-06, Vol.57 (6), p.755-760

Ort / Verlag

Berlin: Springer

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this phase I study was to determine the maximum-tolerated dose (MTD) in elderly patients with small-cell lung cancer (SCLC). Patients aged over 75 years with previously untreated SCLC were enrolled in this study. Both topotecan and cisplatin were administered on days 1-3 and repeated every 3 weeks. The starting dose of topotecan was 0.5 mg/m2/day, while cisplatin was fixed at the dose of 20 mg/m2/day. Patients with limited disease (LD) SCLC received thoracic irradiation after the completion of chemotherapy. Twenty-one elderly patients were enrolled in this study and received a total of 59 cycles. The major hematological toxicity was neutropenia and non-hematological toxicities including diarrhea were generally mild and reversible. The MTD of topotecan was determined as 1.2 mg/m2/day. The recommended phase II study dose of topotecan was determined as 1.0 mg/m2/day with cisplatin 20 mg/m2/day daily for 3 days. An objective response was observed in 6 of 10 patients (60%) with LD-SCLC and 6 of 11 (55%) with extensive disease (ED) SCLC. The median survival time in patients with LD-SCLC and those with ED-SCLC were 16.0 and 11.0 months, respectively. The combination chemotherapy of 3-day topotecan and cisplatin appears to be tolerable and effective in elderly patients with SCLC.